Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Mercedes Santoro

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Plos One|January 24, 2013
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencingValentina Svicher, Valeria Cento, Gabriella Rozera, et al.
Viruses|August 26, 2023
Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line RegimensJoseph Fokam, Collins Ambe Chenwi, Desire Takou, et al.
Plos One|August 14, 2015
Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central ItalyLavinia Fabeni, Claudia Alteri, Nicoletta Orchi, et al.
The Journal of Antimicrobial Chemotherapy|March 14, 2026
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencingDaniele Armenia, Claudia Alteri, Valeria Micheli, et al.
AIDS Research and Human Retroviruses|April 2, 2011
Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in ItalyNazle Mendonca Collaço Véras, Maria Mercedes Santoro, Rebecca R Gray, et al.
BMC Infectious Diseases|October 13, 2023
EuCARE-POSTCOVID Study: a multicentre cohort study on long-term post-COVID-19 manifestationsBenedetta Varisco, Francesca Bai, Sara De Benedittis, et al.
Plos One|August 26, 2014
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTDaniele Armenia, Cathia Soulie, Domenico Di Carlo, et al.
The Journal of Antimicrobial Chemotherapy|November 21, 2022
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individualsAlex Durand Nka, Yagai Bouba, Georges Teto, et al.
AIDS Research and Human Retroviruses|March 16, 2012
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in ItalyMaria Mercedes Santoro, Claudia Alteri, Luigi Ronga, et al.
Scientific Reports|October 26, 2018
Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalenceClaudia Alteri, Lavinia Fabeni, Rossana Scutari, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Plos One|January 24, 2013
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencingValentina Svicher, Valeria Cento, Gabriella Rozera, et al.
Viruses|August 26, 2023
Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line RegimensJoseph Fokam, Collins Ambe Chenwi, Desire Takou, et al.
Plos One|August 14, 2015
Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central ItalyLavinia Fabeni, Claudia Alteri, Nicoletta Orchi, et al.
The Journal of Antimicrobial Chemotherapy|March 14, 2026
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencingDaniele Armenia, Claudia Alteri, Valeria Micheli, et al.
AIDS Research and Human Retroviruses|April 2, 2011
Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in ItalyNazle Mendonca Collaço Véras, Maria Mercedes Santoro, Rebecca R Gray, et al.
BMC Infectious Diseases|October 13, 2023
EuCARE-POSTCOVID Study: a multicentre cohort study on long-term post-COVID-19 manifestationsBenedetta Varisco, Francesca Bai, Sara De Benedittis, et al.
Plos One|August 26, 2014
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTDaniele Armenia, Cathia Soulie, Domenico Di Carlo, et al.
The Journal of Antimicrobial Chemotherapy|November 21, 2022
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individualsAlex Durand Nka, Yagai Bouba, Georges Teto, et al.
AIDS Research and Human Retroviruses|March 16, 2012
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in ItalyMaria Mercedes Santoro, Claudia Alteri, Luigi Ronga, et al.
Scientific Reports|October 26, 2018
Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalenceClaudia Alteri, Lavinia Fabeni, Rossana Scutari, et al.
Pageof 14